Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals, Inc. REGN lost 6.3% in a month compared with the industry’s decline of 2.8% ... Regeneron records net product sales of Eylea in the United States and Bayer records ...

Regeneron Pharmaceuticals, Inc. REGN delivered better-than-expected fourth-quarter 2022 results even though Eylea sales declined. Dupixent maintained its stellar performance, with progress on ...

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea. ... Eylea sales have been under pressure in 2023 due to competition from Roche’s RHHBY ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket on Thursday after net product sales of Eylea in the U.S. fell. even as the company's Q1 results beat estimates.

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.

In the first quarter of 2023, EYLEA sales came in at $1.43 billion, which was a 5% decline. Not superb, but at the same time not that big of a decline in light of competition from Roche's Vabysmo ...

Aug 6 (Reuters) - The explosive growth in the sales of Regeneron Pharmaceuticals Inc's Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing. Shares of ...

Eylea delivered an 8% increase in sales last year, ... Regeneron and its Eylea partner Bayer are in a serious competition with Roche in the macular degeneration arena. ... a 24% decline from 2021.

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.